TransCode amends preferred stock terms: caps conversion at 19.9% of Oct 8 common, removes delisting conversion right

Transcode Therapeutics, Inc.

Filed Amended and Restated Certificate of Designation for Series A and B Preferred on Oct 27, 2025.
Caps aggregate conversion at 19.9% of common outstanding as of Oct 8, 2025, per Nasdaq listing rules.
Removed holders' right to convert preferred into common upon delisting from Nasdaq.
Amendment approved by majority of preferred holders and board; no new shares issued.
Expects proxy statement for conversion approval and change-of-control proposals under Nasdaq rules.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Transcode Therapeutics, Inc.: Amended Section 6.1.1 of the Certificate of Designation to clarify conversion limits and removed the holder's right to convert Preferred Stock into Common Stock upon delisting from Nasdaq (effective 2025-10-27).

Change: charter amendment
Effective: 2025-10-27

Exact text from the filing

The Amended and Restated Certificate of Designation amended Section 6.1.1 of the Prior Certificate to clarify that for as long as the Purchase Agreement remains in effect and for as long as any shares of Preferred Stock remain outstanding, prior to receipt by the Company of the stockholders’ approval of the conversion of the applicable series of Preferred Stock into shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), in accordance with the listing rules of the Nasdaq Stock Market, as set forth in the Purchase Agreement, the Company shall not issue pursuant to the Purchase Agreement and Section 6.1.1 of the Amended and Restated Certificate of Designation more than an aggregate of 19.9% of the Common Stock outstanding as of October 8, 2025. In addition, the Amended and Restated Certificate of Designation removed the ability of a holder of Preferred Stock to convert, at the option of such holder, the Preferred Stock into Common Stock in the event of a delis

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Transcode Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-102361

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.